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Abstract: Small cell lung cancer (SCLC) represents about 15% to 20% of all lung cancers. 
Chemotherapy is the cornerstone of the treatment, cisplatin–etoposide combination being the most 
used combination as ﬁ  rst-line therapy. Despite high initial chemosensitivity, most SCLC patients 
will experience relapse sooner or later. Unfortunately, second-line chemotherapy does not result in 
a high response rate like ﬁ  rst-line therapy, most patients having developed wide chemoresistance. 
This chemoresistance is far more important in refractory patients, ie, those who never responded 
to ﬁ  rst-line therapy or who relapsed within 3 months after the end of chemotherapy, than in 
sensitive patients, ie, those who relapse more than 3 months after the end of chemotherapy. 
Topotecan, a topoisomerase I inhibitor, is the most studied drug in this second-line setting and 
has proved its efﬁ  cacy as a single agent and in combination. A phase III trial comparing oral 
topotecan to best supportive care (BSC) in relapsed SCLC demonstrated a signiﬁ  cant survival 
beneﬁ  t as well as a better quality of life. Although the usual schedule is 1.5 mg/m2, days 1–5 
intravenously, it is not convenient for patients with relapsed SCLC, especially those who are 
refractory because of their short survival expectation. Oral topotecan is of similar efﬁ  cacy and 
much more convenient with limited stay in a treatment unit and has a comparable toxicity proﬁ  le 
for these patients with short expected survival. Combination of topotecan with platinum salts 
or taxanes does not seem to improve further the outcome of the patients and thus single-agent 
therapy with topotecan is the standard treatment for relapsed SCLC.
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Introduction
Small cell lung cancer (SCLC) is a highly chemosensitive tumor but, unfortunately, 
not chemocurable. After a response rate of about 80%, sooner or later most of the 
patients will relapse, especially those with extensive disease stage (ED) at diagnosis. 
Response to second-line therapy is a rare event and eventually most patients who 
relapse die of their disease within a few weeks. However, among the population of 
patients who experience recurrence of their disease there are characteristics that will 
affect the probability of response to second-line therapy. Thus, it is very important 
to classify these patients, especially in a clinical trial setting, in order to make proper 
comparisons between drugs.
Topotecan is a topoisomerase I inhibitor which was ﬁ  rst developed for ovarian can-
cer and recurrent SCLC and has been the most studied drug for the latter indication.
Outcome of SCLC patients under treatment
Whenever extensive work-up is performed, with modern imaging procedures, at least 
two-thirds of the patients have ED at diagnosis, meaning that tumor and connections 
cannot be included within a radiation therapy port.
Standard treatment of SCLC is based on chemotherapy, mainly the cisplatin – 
etoposide combination which has been shown to be the best (Sundstrom et al 2002). OncoTargets and Therapy 2008:1 80
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A third or even a fourth drug may be added for PS 0-1 patients 
with better results at the expense of increased toxicity (Pujol 
et al 2001). In cases of limited disease stage (LD), radiation 
therapy is given concomitantly with chemotherapy or on 
an early alternating schedule, with a signiﬁ  cant survival 
beneﬁ  t compared to chemotherapy alone (Warde and Payne 
1992). In patients with ED, thoracic radiation therapy is not 
indicated. In LD, prophylactic cranial irradiation is indicated 
in cases of complete response (Auperin et al 1999). Recently, 
prophylactic cranial irradiation has also been discussed for 
ED patients who achieve response to induction treatment 
(Slotman et al 2007).
Median survival time is highly dependent on the extent 
of disease. In LD, median survival time is around 18 months 
with a 2-year survival rate of 33% to 40% and a 5-year sur-
vival rate of about 10%, whereas in ED, median survival time 
is around 10 to 12 months with almost no survival at 2 years. 
These ﬁ  gures have not been modiﬁ  ed recently even though 
a 2-month median survival improvement has been shown in 
clinical trials over 20 years, an improvement that parallels the 
introduction of cisplatin (Chute et al 1999). Modifying the 
drugs provides no improvement in survival: the better results 
of cisplatin – irinotecan compared to cisplatin – etoposide 
observed in Japanese patients were not conﬁ  rmed in European 
and North American patients (Hanna et al 2006). Adminis-
tration of very high doses of chemotherapy supported by 
transfusion with peripheral blood progenitor cells (PBPCs) 
provides no improvement (Leyvraz et al 2008). Shortening 
the treatment by decreasing the interval between two cycles 
did not improve survival (Pujol et al 1997), nor did adding 
interferon as an adjuvant to chemotherapy (Van Zandwick 
et al 1997). Adding an antiangiogenic drug (thalidomide) 
improves survival at the expense of severe neurotoxicity, 
which precludes its use (Pujol et al 2007). Other antiangio-
genics (marimastat) did not demonstrate any beneﬁ  t. Main-
tenance therapy, which was usual until the 1980s, proved 
to have no effect on patient survival (Giaccone et al 1993) 
and nowadays 4 to 6 cycles are administered to patients. 
Even though a dose-response relationship was demonstrated 
decades ago (Cohen et al 1977), there has been no improve-
ment beyond doses that can be safely administered without 
the need for PBPCs (Arriagada et al 1993).
Refractory and sensitive patients
About 95% of the patients with SCLC relapse after initial treat-
ment, with overall survival expectation of only a few weeks. 
SCLC tumors develop a broad chemoresistance induced by 
the existence of drug-resistant clones at the beginning of the 
treatment (more frequent in ED) or the occurrence of these 
clones during treatment. This uncertainty explains why treat-
ment of SCLC at relapse has been performed empirically 
rather than based on the knowledge of speciﬁ  c mechanisms 
of resistance involved (Huisman et al 1999).
Patients who relapse 3 months after ﬁ  rst-line therapy 
are commonly called refractory, and patients who relapse at 
least 3 months after therapy are called sensitive. Refractory 
patients comprise those who never responded to induction 
therapy and progressed during this induction treatment 
together with those who responded but relapsed quickly 
within 3 months after the end of induction chemotherapy. 
When cisplatin and/or etoposide were not part of the initial 
treatment, high levels of response were published with 
this combination in relapsed patients, although in the early 
reports, duration of response rate to ﬁ  rst line and duration 
of treatment-free interval after induction chemotherapy were 
not always detailed (Andersen et al 1990).
The usual practice is to reintroduce whenever possible, 
bearing in mind cumulative toxicity, the ﬁ  rst-line therapy in 
those patients who relapse later, as the highest response rates 
were reported in this setting (Huisman et al 1999). However, 
one must be aware that the length of treatment-free interval 
before relapse depends on how frequent and exhaustive are 
disease assessments after the end of treatment. These data 
are never stated in published studies although they may 
have important effects on response rate. Moreover, in some 
studies, initial treatment was rechallenged if the treatment-
free interval was 8 months (Postmus et al 1987) or even 
2 years (Batist et al 1983). Although these studies are old, 
it is unlikely that the conclusions drawn would differ at this 
time, since there has been no modiﬁ  cation in the induction 
treatment of this disease.
Studies devoted to second-line therapy in SCLC should 
be stratiﬁ  ed on the refractory or sensitive character of the 
disease. Investigations of new agents with potentially no 
cross-resistance with induction therapy should be performed 
in refractory patients or sensitive patients who cannot be 
retreated with the same initial combination. Rechallenging 
the initial combination should be all the more considered as 
the treatment-free interval is 6 months (Eckardt 2003).
Topotecan in relapsed SCLC
This drug has been the most widely studied in the setting 
of relapsed SCLC. Topotecan, a semisynthetic, water-
soluble analog of camptothecin, is a speciﬁ  c inhibitor of 
the nuclear enzyme topoisomerase I, which interferes with 
DNA replication and transcription. Inhibition of this enzyme OncoTargets and Therapy 2008:1 81
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produces lethal DNA damage. Phase I studies resulted in a 
recommended dose and schedule of 1.5 mg/m²/day intrave-
nously during 5 days every 3 weeks (Rowinsky et al 1992).
Phase II studies with topotecan 
as a single agent
Intravenous schedule
Only phase II studies published as full papers are discussed. 
Ardizzoni et al (1997) evaluated topotecan with this recom-
mended schedule in 47 refractory and 45 sensitive patients 
with relapsed SCLC. Patients were less than 75 years old, 
PS 0–2, treated with one previous chemotherapy line. 
Previous rechallenge with the same chemotherapy regi-
men was allowed (7 patients). Brain metastases were not 
an exclusion criterion if asymptomatic. As a whole, there 
were 20 responses (21.7%, 95% CI 13.8%–31.6%), 3 in 
the refractory group (6.3%) and 17 (37.8%) in the sensi-
tive group. There were 11 patients with brain metastases, 
and all who achieved a response outside the brain also 
responded at the brain level. Median duration of response 
was 7.6 months (95% CI 5.1–12.2 months). Median time 
to progression was 2.8 months (95% CI 2.2–3.9 months) 
and median overall survival was 5.4 months (95% CI 
4.8–6.3 months) –6.9 months for sensitive patients and 
4.7 months for refractory patients. Toxicity of topotecan 
was mainly hematological (75% of grade 3–4 neutropenia, 
11.8% grade 3–4 anemia and 29.5% of grade 3–4 throm-
bopenia) and not cumulative. Non-hematological toxicity 
was mild.
Another phase II study was performed in 32 patients 
refractory to ﬁ  rst-line cisplatin – etoposide therapy (Perez-
Soler et al 1996). Three responses were observed (response 
rate 11%), of short duration for 2 (7 and 8 weeks). Median 
survival time was 20 weeks.
Topotecan given as salvage therapy in refractory 
patients pre-treated with irinotecan (+ cisplatin or carbo-
platine) did not appear effective, with 2 responses among 
17 patients and a median survival time of 3.4 months (95% 
CI 1.7–5 months) (Park et al 2008).
A multicenter phase II study (Huber et al 2006) was 
performed in 170 patients in order to evaluate prospectively 
the efﬁ  cacy and safety of   topotecan with a starting dose of 
1.25 mg/m2 during 5 days and with dose adjustment according 
to toxicity. Patients with recurrent or refractory SCLC were 
stratiﬁ  ed according to pre-treatment with a platinum-containing 
or platinum-free regimen and their response to pre-treatment. 
Patients were PS 0–2 and should have received only one 
previous line. In cases of no grade 3–4 toxicity after the ﬁ  rst 
cycle, dose could be augmented to 1.5 mg/m²/day. Further 
increase in doses was left to the investigator appreciation 
in case of the absence of grade 3–4 toxicity. Topotecan 
dose was reduced by 0.25 mg/m2 in cases of grade 4 neu-
tropenia lasting 7 days or longer, or complicated by fever 
or infection; platelet count of 25,000/μL, or neutrophil 
count of 1500 cells/μL1 and platelet count 100,000/μL 
on day 22; and in cases of grade 3 or 4 non-hematological 
toxicity (except for nausea, vomiting and alopecia). In any 
case, the minimum topotecan dose had to be 1.0 mg/m2/day. 
No dose re-escalation was allowed. In case of complete 
response, 4 cycles were to be given. In cases of partial 
response or stable disease, treatment was given until progres-
sion or unacceptable toxicity.
A total of 76.8% of patients had performance status ECOG 
0-1. The majority of patients (73.2%) had distant metastatic 
disease and 63.4% of patients had received a platinum-based 
primary therapy. The overall response rate to primary therapy 
was 76.8%. In total, 34.8% of patients were refractory, 
whereas 65.2% of patients were sensitive to prior therapy. 
The median time to progression after ﬁ  rst-line therapy was 
191 days. A total of 514 topotecan courses were received by 
164 patients. Of these, 22.6% of patients (n = 37) received 
only 1 course of therapy, 52 patients (31.7%) received 
2 courses, 6 patients received at least 3 courses, and 2.4% 
(n = 4) of patients received 8 courses. In 58.2% of courses 
(n = 299), the starting dose was maintained. The topotecan 
dose had to be reduced to 1.0 mg/m2/day in 8.9% (n = 46) of 
courses. The targeted dose of topotecan (1.5 mg/m2/day) was 
reached in 32.9% (n = 169) of courses. In the ﬁ  rst course, 
the topotecan dose was administered as a starting dose of 
1.25 mg/m2/day to 98.2% of patients (n = 161). This starting 
dose was maintained in 46.5% of patients (n = 59) in course 
two. Dose was escalated to 1.5 mg/m2/day of topotecan in 
37.8% of patients (n = 48), whereas in 15.7% (n = 20) it 
was reduced to 1.0 mg/m2/day. Median dose intensity of all 
administered cycles was 1.25 mg/m2/day.
The overall response rate was 14.1% with one complete 
response and 23 (13.5%) partial responses. Stable disease 
was observed in 25.9% and progressive disease in 60% 
of patients. No difference in response rates was seen 
between patients with or without platinum-containing 
pre-treatment. On the other hand, patients who had been 
refractory to primary therapy achieved a lower response 
rate (8.6% versus 17.1% in sensitive patients). Median 
duration of response was 13.6 (3.0–47.9) weeks and 
was not significantly different among the subgroups. 
Median time to progression for all patients was 8.0 weeks OncoTargets and Therapy 2008:1 82
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(interquartile range 0.1–53.6 weeks). Median survival 
time was 23.4 weeks (interquartile range 0.9–92.4 weeks). 
Fifteen percent of patients were alive at 1 year.
Major side-effects were neutropenia and leukopenia, 
whereas anemia and thrombocytopenia were less common. 
Grade 3 and 4 neutropenia occurred in 27.7 and 27.6% of 
patients, and in 31.5 and 6.9% of treatment courses, respec-
tively. The incidence thrombocytopenia was grade 3 and 4 
in 10.3% and 5.0% of treatment courses (23.5% and 13.5% 
of patients), respectively. In total, 10% of patients received 
platelet transfusion (3.3% of treatment courses). Anemia 
grade 3 and 4 was less common (5.5% and 0.6% of all 
courses, respectively); in 3.6% of courses, red blood cell 
(RBC) transfusion was performed.
This study conﬁ  rms that a reduced dose of topotecan 
1.25 mg/m²/day is as effective as 1.5 mg/m²/day, with less 
hematological toxicity.
Oral topotecan
In a phase II randomized study iv topotecan with the 
classical schedule (1.5 mg/m²/day) was compared to oral 
topotecan (2.3 mg/m²/day, days 1–5, every 3 weeks) (von 
Pawel et al 2001), in a total of 106 sensitive patients (70% 
males). Fifty-two received oral topotecan and 54 received 
iv topotecan. Seventy percent had extensive disease and 
approximately 70% had also received prior radiotherapy. 
For both treatment regimens, the median number of courses 
was 4 (range: 1–12).
In this patient population, 12 patients (23%) receiving 
oral topotecan and 8 patients (15%) receiving iv topotecan 
responded to treatment. Among these, 3 (1 oral and 2 iv) had 
a complete response. The difference in response rates (oral 
vs iv) was 8.3% (95% CI, –6.6% to 23.1%), indicating that 
the true underlying response rate with the oral formulation 
is at worst 6.6% lower than that of the iv formulation, which 
is not a clinically meaningful difference. Sex (p = 0.021) and 
previous radiotherapy (p = 0.015) were statistically associ-
ated with increased probability of response. Female patients 
were 4.5 times more likely to respond than males and patients 
with no prior radiotherapy 4.9 times more likely to respond. 
Accounting simultaneously for all of the aforementioned 
prognostic factors in the logistic regression model, the oral 
topotecan patients were 1.6 times more likely to respond than 
the iv topotecan patients (95% CI for odds ratio: 0.50–5.15). 
In the multivariate model for response, patients were 30% 
more likely to respond than were those with less than 
6 months time duration; however, this result was not statisti-
cally signiﬁ  cant. The median survival was 32 weeks in the 
oral group and 25 weeks in the iv group. The multivariate 
analysis showed that absence of liver metastases and PS  2 
were both favorable independent prognostic factors.
There was also signiﬁ  cant symptom improvement espe-
cially for chest pain, cough, dyspnea, anorexia, insomnia, 
hoarseness, fatigue, and interference with daily activity 
(from 16% to 42%). Again, the principal side effect was 
neutropenia, which occurred at a higher incidence in patients 
treated with iv topotecan. Myelosuppression was consistent 
with topotecan’s profile, non cumulative and generally 
reversible. After use of oral topotecan, grade 4 neutropenia 
was observed in 35.3% of patients, whereas administration 
of iv topotecan resulted in grade 4 neutropenia, occurring in 
67.3% of patients (p = 0.001); oral courses, 11.8%; iv courses, 
32.5%. Two patients, 1 in each group, died of febrile neu-
tropenia. The incidence of severe thrombocytopenia was 
similar with both treatment regimens: 27.5% of patients 
(8.0% of courses) in the oral topotecan group and 24.5% of 
patients (7.7% of courses) in the iv topotecan group. Platelet 
transfusions were given to 14.8% of patients treated with iv 
topotecan. The incidence of grade 3 or 4 anemia was also 
similar after either oral or iv topotecan: 31.4% of patients 
(10.4% of courses) in the oral topotecan group, and 30.2% of 
patients (10.5% of courses) in the iv topotecan group. RBC 
transfusions were given to 42.3% and 38.9% of patients in 
the respective groups.
Non-hematological toxicity consisted essentially of nau-
sea and vomiting, mostly grade 1 and 2, but grade 3 nausea 
was observed in 11.5% of patients receiving oral topotecan 
and 3.7% of patients receiving iv topotecan. Grade 3 diarrhea 
was observed in 7.7% of the patients of oral group versus 
none of the iv group.
Weekly schedule
This schedule (topotecan 4 mg/m²/week) has been developed 
for ovarian cancer and was investigated in relapsed SCLC 
(Shah et al 2007). The rationale is based on preclinical studies 
and on the fact that topotecan, like taxanes and gemcitabine, 
which have demonstrated signiﬁ  cant antitumor activity using 
weekly dosing schedule, is a S-phase speciﬁ  c drug. There was 
no response among 22 sensitive patients, and thus there is no 
indication to use this schedule at the present time.
Phase II studies with topotecan-based 
combinations
An EORTC phase II study of topotecan associated to cisplatin 
was performed in 110 patients among which 68 were sensi-
tive (Ardizzoni et al 2003). Prior chemotherapy containing OncoTargets and Therapy 2008:1 83
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cisplatin was permitted only in case of a partial response and 
completion of therapy at least 6 months ago. Cisplatin was 
given at the dose of 60 mg/m² on day 1 and topotecan at the 
dose of 0.75 mg/m² on days 1–5 every 3 weeks. A median 
number of 4 cycles were delivered to the sensitive patients 
and 3 to the refractory patients. Nineteen partial and 1 com-
plete responses were obtained in the sensitive group (29%), 
whereas 10 partial responses occurred in the refractory group 
(23.8%). Median survival time was 6.4 months (95% CI 
5.8–8 months) for the sensitive group and 6.1 months (95% 
CI 5.6–7.7 months) for the refractory group. Median time 
to progression was 4.7 months and 3 months, respectively. 
Grade 3–4 neutropenia was observed in approximately 75% 
of the patients and grade 3–4 thrombopenia in 74% of the 
sensitive patients and 64% of the refractory patients. Ten 
early deaths occurred, of which 7 could have been due to 
toxicity.
An other phase II study (Christodoulou et al 2006) 
evaluated the combination of cisplatin and topotecan with 
a different schedule: 20 mg/m² days 1–3 for cisplatin and 
0.9 mg/m² days 1–3 for topotecan every 3 weeks. Thirty-
four patients were included, 21 of whom were sensitive. 
The response rate was 18% (6 patients), with 2 complete 
responses and 3 partial responses in the sensitive group and 
only 1 partial response among the refractory group. Median 
survival time was 6.5 months for all patients (7.8 for sensitive 
and 6.2 for refractory patients). Median time to progression 
was 4.4. months for all patients (5.9 and 3.2 respectively for 
sensitive and refractory patients). Grade 3–4 neutropenia was 
observed in 42% of patients and grade 3–4 thrombocytopenia 
in 15%, less frequently than in the 5-day schedule.
Finally, topotecan and paclitaxel combination was inves-
tigated on a weekly schedule: paclitaxel 70 mg/m² and topo-
tecan 1.75 mg/m² on days 1, 8, 15 repeated every 28 days in 
45 sensitive patients (Stathopoulos et al 2006). Among these, 
11 had already received paclitaxel as ﬁ  rst-line therapy. There 
was 1 complete response and 10 partial responses. Median 
time to progression was 4 months and median survival time 
was 7 months (95% CI 4.2–9.8]. Grade 3–4 neutropenia was 
observed in 27% of the patients, grade 3 thrombocytopenia 
in 2.44%. The same combination has also been tested by 
the North Central Cancer Treatment Group with 84 patients 
accrued, but 78 eligible (Dy et al 2006). The treatment 
scheme was topotecan 1.0 mg/m² days 1–3 and paclitaxel 
200 mg/m² day 3 every 4 weeks. After 6 patients (3 refractory 
and 3 sensitive) were included with good tolerance, the dose 
of topotecan was increased to 1.25 mg/m²/day. Refractory 
patients received a median of 3 cycles and sensitive patients 
a median of 4 cycles. The overall objective response rate of 
patients with refractory disease was 8.7%; median time to 
progression was 2.8 months (95% CI 2.0–3.7) and accrual 
was closed after 23 patients due to insufﬁ  cient clinical activ-
ity of this combination. The overall objective response rate 
of patients in sensitive relapse was 27.3%; median time to 
progression was 3.7 months (CI 2.2–5.3). Median survival 
time was 5.7 months in the refractory group (95% CI 4.8–7.5) 
and 6.9 months in the sensitive group (95% CI 5.8–8.4). The 
most frequently encountered grade 3 and 4 toxicities were 
neutropenia (92%), leukopenia (77%), thrombocytopenia 
(29%), fatigue (22%), and dyspnea (10%).
Phase III studies
In a randomized multicenter study, von Pawel et al (1999) 
compared cyclophosphamide, adriamycin, and vincristine 
(CAV) with topotecan as a single agent in patients who had 
relapse at least 60 days after completion of initial therapy. 
Patients received either topotecan as a 30 min/day infusion 
for 5 days every 21 days, or CAV infused on day 1 every 
21 days. A total of 211 patients were enrolled. The response 
rates were 24.3% in patients treated with topotecan and 
18.3% in patients treated with CAV (p = 0.285). Median 
times to progression were 13.3 weeks for the topotecan arm 
and 12.3 weeks for the CAV arm. Median survival times were 
25 weeks for topotecan and 24.7 weeks for CAV. However, 
the size of the population of patients did not meet the crite-
rion for a non inferiority study. The proportion of patients 
with symptom improvement (dyspnea, anorexia, hoarseness, 
fatigue, interference with daily activity) was greater in the 
topotecan arm than in the CAV group for 4 of the 8 symptoms 
evaluated. The authors concluded that topotecan was at least 
as effective as CAV in the treatment of patients with recurrent 
SCLC and resulted in improved symptom control. However, 
toxicity rates were high in both arms and alternative dose 
schedules of topotecan are currently favored.
Oral topotecan was compared to iv topotecan in a phase III 
study performed in 309 sensitive patients with relapsed SCLC 
(Eckardt et al 2007). Patients were assigned to treatment 
with either oral topotecan 2.3 mg/m2/day on days 1–5 or iv 
topotecan 1.5 mg/m2/day on days 1–5 every 21 days. Primary 
end point was response rate. In an intent-to-treat analysis, 
response rates were 18.3% (95% CI 12.2–24.4) with oral 
topotecan (n = 153) and 21.9% (95% CI 15.3–28.5) with iv 
topotecan (n = 151). Median survival time was 33.0 weeks for 
oral and 35.0 weeks for iv topotecan; 1- and 2-year survival 
rates were 32.6% and 12.4% for oral topotecan, respec-
tively, and 29.2% and 7.1% for iv topotecan, respectively. OncoTargets and Therapy 2008:1 84
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Grade 3–4 toxicity in patients who received oral and iv topo-
tecan was: leukopenia in 65.7% and 75.3%, neutropenia in 
73.2% and 87.8%, thrombocytopenia in 48.7% and 43.3%, 
grade 3 or 4 anemia in 23% and 31%, and sepsis in 3% 
and 3%, respectively. The most frequent non-hematologic 
adverse events (all grades) included nausea (43% oral; 42% 
iv), alopecia (26% oral; 30% iv), fatigue (31% oral; 36% iv), 
and diarrhea (36% oral; 20% iv).
Spiro et al 1989 demonstrated the favorable effect of 
chemotherapy on survival in relapsed SCLC in a randomized 
study comparing two durations of chemotherapy in ﬁ  rst line 
then chemotherapy with methotrexate and doxorubicin to no 
treatment in second line. In a later, randomized study (O’Brien 
et al 2006), in patients with relapsed SCLC not considered as 
candidates for standard iv therapy, best supportive care (BSC) 
alone (n = 70) or oral topotecan (2.3 mg/m²/day, days 1–5, 
every 21 days) plus BSC (topotecan; n = 71) were compared. 
In an intent-to-treat analysis, survival was prolonged in the 
topotecan group (p = 0.0104). Median survival time was 
13.9 weeks with BSC (95% CI 11.1–18.6 weeks), and 25.9 
weeks with topotecan (95% CI 18.3–31.6 weeks). Partial 
responses were seen in 7% of patients receiving topotecan, 
with an additional 44% of patients achieving stable disease. 
Patients receiving topotecan had slower quality of life dete-
rioration and greater symptom control. Principal toxicities 
with topotecan were hematologic: grade 4 neutropenia, 33%; 
grade 4 thrombocytopenia, 7%; and grade 3/4 anemia, 25%. 
Toxic deaths occurred in 4 patients (6%) in the topotecan 
arm. Early death rates (within 30 days after randomization) 
were 13% with BSC and 7% with topotecan.
Table 1 shows the results and Table 2 grade 3–4 toxicity 
observed with topotecan as a single agent in phase II and 
III studies.
Conclusion
Response rate to second-line therapy in SCLC patients is 
very low due to wide chemoresistance. However, response 
rate is highly dependent on the response to ﬁ  rst-line therapy 
and on the duration of treatment-free interval. Topotecan, a 
topoisomerase I inhibitor, is an active drug in relapsed SCLC. 
It has at least partially no cross-resistance with other drugs 
commonly used in the treatment of SCLC except probably 
irinotecan. The response rate observed with topotecan is 
between 6% and 11.8% in refractory patients and between 
15% and 37% in sensitive patients. Median survival time is 
between 3.6 and 5.4 months in refractory patients and 5 and 
8 months in sensitive patients.
Patients with relapsed SCLC are often heavily pretreated 
and myelosuppression is the main toxicity expected. The 
usual 5-day schedule results in a quite important grade 3–4 
hematological toxicity and is not very convenient for these 
patients with expected short-term survival. Oral topotecan 
appears to be as active and less toxic than iv topotecan, and 
is much more convenient. Weekly topotecan at this time does 
not appear as being active, and although more convenient 
than the 5-day iv schedule, it is not recommended. The com-
bination of topotecan with either platinum salts or taxanes 
in the second-line setting is not superior to single-agent 
topotecan therapy. Thus, topotecan is indicated in refractory 
patients, taking into account the beneﬁ  t/risk ratio in this poor 
Table 1 Phase II/III studies of topotecan as single agent in relapsed SCLC
Schedule Author Year Phase No patients RR % RD (months) TTP (months) MST (months)
iv 1.5 mg/m² days 1–5 Ardizzoni 1997 II 45 s 37 4.75 4.06 6.9
47 r 6 7.04 1.9 4.7
iv 1.5 mg/m² days 1–5 Perez-Soler 1998 II 32 r 11 – – 4.6
iv 1.5 mg/m² days 1–5 Park 2008 II 17 r 11.8 – 1.7 3.4
iv adjusted to toxicity Huber 2006 II 111 s 17.1 3.12 1.84 5.37
59 r 8.6
iv 1.5 mg/m² oral  Von Pawel 2001 R II 54 s 15 4.15 3.42 5.74
2.3 mg/m² days 1–5 52 s 23 3.19 3.00 7.34
Weekly 4 mg/m² Shah 2007 II 22 s 0 – 1.37 5.00
iv 1.5 mg/m² days 1–5 Von Pawel 1999 III 211 ± s 24.3 3.3 3.05 5.74
oral 2.3 mg/m² O’Brien 2006 III 71a 7 – – 5.94
oral 2.3 mg/m² Eckardt 2007 III 153 18.3 4.2 2.73 7.57
iv 1.5 mg/m² days 1–5 151 21.9 5.83 3.35 8.03
aunsuitable for iv chemotherapy.
Abbreviations: iv, intravenous; s, sensitive; r, refractory; R, randomized; RR, response rate; RD, response duration; TTP, time to progression; MST, median survival time.OncoTargets and Therapy 2008:1 85
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prognosis population and using the most convenient schedule 
(oral), and in sensitive patients when rechallenging the ﬁ  rst-
line treatment is not indicated.
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